Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
⚠ No validated human dose. This compound is not FDA-approved and has no peer-reviewed human dose-finding trials. The figures below are research conventions extrapolated from preclinical (animal/in‑vitro) and community sources — not validated clinical dosing. Treat them as study references only. Research use only; not medical advice.
GW-501516 (Cardarine) is a selective PPARdelta receptor agonist developed by GlaxoSmithKline. It dramatically enhances endurance, fat oxidation, and lipid metabolism. Development was abandoned after animal studies showed cancer at extreme doses. It is not a SARM.
Protocol Overview
Compound
GW-501516 (Cardarine / Endurobol)
Category
PPARdelta Receptor Agonist (Metabolic Modulator)
Mechanism
Activates PPARdelta, shifting cellular energy metabolism from glucose to fatty acid oxidation. Upregulates fat-burning genes, increases mitochondrial biogenesis, improves lipid profile (HDL up, LDL and triglycerides down), and dramatically enhances endurance capacity
Half-Life
16-24 hours
Form
Oral liquid or capsule
Route
Oral
Frequency
Once daily
Cycle Length
8-12 weeks
Dosing Protocol
Protocol
Dose
Frequency
Route
Duration
Standard
10 mg
1x daily
Oral
8 weeks
Enhanced
15 mg
1x daily
Oral
8-10 weeks
Maximum
20 mg
1x daily
Oral
8-12 weeks
Expected Timeline
Week 1-2
Enhanced endurance within days. Ability to sustain cardiovascular exercise significantly increased.
Week 3-4
Major endurance and fat loss effects. Lipid panel improves (HDL increase, triglycerides decrease).
Week 5-6
Peak fat loss effects. Body composition changes clearly visible. Endurance at maximum enhancement.
Week 7-8
Continued benefits. Lipid profile significantly improved. Good stopping point for standard cycle.
Week 9-12
Extended cycle for experienced users. No hormonal suppression to manage.
Side Effects & Monitoring
Common Side Effects
Generally very well tolerated at standard doses
Rare headaches
Occasional mild GI discomfort
Potential for increased appetite
Precautions
Cancer concerns: rodent studies showed tumor development at high doses over 2 years
No long-term human safety data
Does not suppress testosterone - no PCT needed
Banned by WADA for athletic competition
Individual risk assessment essential given cancer data
The cancer risk is debated. Rodent studies used doses far exceeding typical human use (100x+) for extended periods. No human cancer data exists. However, the lack of long-term human safety data means the risk cannot be definitively quantified.
Does Cardarine suppress testosterone?▼
No. GW-501516 does not interact with androgen receptors or the HPTA axis. No PCT is needed. It is commonly stacked with SARMs because it adds endurance and fat loss without additional suppression.
How quickly does Cardarine work?▼
Many users report noticeable endurance improvement within 1-3 days of first dose. The effect on cardio capacity is often described as dramatic. Fat loss effects build over several weeks.
⚠ Before any use: human safety data is limited or absent for many of these compounds. Consult a licensed healthcare provider first — especially if you are pregnant or nursing, have a medical condition, or take other medications.
This site uses minimal cookies for functionality. No tracking cookies are used. See our Privacy Policy.
